Derek Brown1, Stephanie Shao2, Ismail Jatoi3, Craig D Shriver2, Kangmin Zhu4. 1. John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, MD, United States. 2. John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, MD, United States; Uniformed Services University, Bethesda, MD, United States. 3. The University of Texas Health Science Center at San Antonio, San Antonio, TX, United States. 4. John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, MD, United States; Uniformed Services University, Bethesda, MD, United States. Electronic address: kzhu@usuhs.mil.
Abstract
BACKGROUND: While differences in CPM use between White and Black patients are well known, it is not clear whether CPM use differs by estrogen/progesterone receptor (ER/PR) status of tumors and whether racial/ethnic differences in the use are affected by ER/PR status, which varies between racial groups. The purpose of this study was to investigate whether CPM usage differs by racial/ethnic group and ER/PR status among patients in the Surveillance, Epidemiology, and End Results (SEER) data. METHODS: The study subjects were women with histologically confirmed unilateral breast cancer who underwent breast surgery between 1998 and 2011. Age-adjusted CPM use as a proportion of all surgically treated patients or all patients who had mastectomy was analyzed by racial/ethnic group, tumor behavior, and ER/PR status. Temporal trends in age-adjusted CPM use were presented by ER/PR status and racial/ethnic group. RESULTS: The analyses stratified by ER/PR status showed significant racial/ethnic differences in age-adjusted CPM use with non-Hispanic White and non-Hispanic Asian/Pacific Islander (API) patients having the most and least CPM use. Age-adjusted CPM use was significantly higher for ER+/PR+ tumors than ER-/PR- ones for each race/ethnicity group among patients with mastectomy. However, among patients with any breast surgeries, the only difference was a higher proportion of CPM use for ER-/PR- tumors (8.6%) than ER+/PR+ tumors (8.0%) in non-Hispanic Whites. CPM use has increased over time in all racial/ethnic groups despite ER/PR status. CONCLUSION: CPM usage was lower not only in non-Hispanic Blacks, but also in non-Hispanic API and Hispanic patients compared to non-Hispanic White patients. CPM usage tended to be higher for ER+/PR+ tumors, but the results varied when different denominators (all mastectomies vs. all breast surgeries) were used.
BACKGROUND: While differences in CPM use between White and Black patients are well known, it is not clear whether CPM use differs by estrogen/progesterone receptor (ER/PR) status of tumors and whether racial/ethnic differences in the use are affected by ER/PR status, which varies between racial groups. The purpose of this study was to investigate whether CPM usage differs by racial/ethnic group and ER/PR status among patients in the Surveillance, Epidemiology, and End Results (SEER) data. METHODS: The study subjects were women with histologically confirmed unilateral breast cancer who underwent breast surgery between 1998 and 2011. Age-adjusted CPM use as a proportion of all surgically treated patients or all patients who had mastectomy was analyzed by racial/ethnic group, tumor behavior, and ER/PR status. Temporal trends in age-adjusted CPM use were presented by ER/PR status and racial/ethnic group. RESULTS: The analyses stratified by ER/PR status showed significant racial/ethnic differences in age-adjusted CPM use with non-Hispanic White and non-Hispanic Asian/Pacific Islander (API) patients having the most and least CPM use. Age-adjusted CPM use was significantly higher for ER+/PR+ tumors than ER-/PR- ones for each race/ethnicity group among patients with mastectomy. However, among patients with any breast surgeries, the only difference was a higher proportion of CPM use for ER-/PR- tumors (8.6%) than ER+/PR+ tumors (8.0%) in non-Hispanic Whites. CPM use has increased over time in all racial/ethnic groups despite ER/PR status. CONCLUSION: CPM usage was lower not only in non-Hispanic Blacks, but also in non-Hispanic API and Hispanic patients compared to non-Hispanic White patients. CPM usage tended to be higher for ER+/PR+ tumors, but the results varied when different denominators (all mastectomies vs. all breast surgeries) were used.
Authors: Patricia A Parker; Susan K Peterson; Yu Shen; Isabelle Bedrosian; Dalliah M Black; Alastair M Thompson; Jonathan C Nelson; Sarah M DeSnyder; Robert L Cook; Kelly K Hunt; Robert J Volk; Scott B Cantor; Wenli Dong; Abenaa M Brewster Journal: J Clin Oncol Date: 2018-07-25 Impact factor: 44.544
Authors: Oluwole Adeyemi Babatunde; Jan M Eberth; Tisha Felder; Robert Moran; Samantha Truman; James R Hebert; Jiajia Zhang; Swann Arp Adams Journal: J Racial Ethn Health Disparities Date: 2020-05-08
Authors: Nisreen Elsayegh; Rachel D Webster; Angelica M Gutierrez Barrera; Heather Lin; Henry M Kuerer; Jennifer K Litton; Isabelle Bedrosian; Banu K Arun Journal: Cancer Med Date: 2018-05-07 Impact factor: 4.452
Authors: Judy C Boughey; Deanna J Attai; Steven L Chen; Hiram S Cody; Jill R Dietz; Sheldon M Feldman; Caprice C Greenberg; Rena B Kass; Jeffrey Landercasper; Valerie Lemaine; Fiona MacNeill; David H Song; Alicia C Staley; Lee G Wilke; Shawna C Willey; Katharine A Yao; Julie A Margenthaler Journal: Ann Surg Oncol Date: 2016-07-28 Impact factor: 5.344